NPPB and hydrops fetalis: The study of Mapelli et al. shows how sacubitril/valsartan have effects on HF biomarkers (in particular decreasing NT-proBNP and ST2 levels), indicating its ability to modulate the underlying pathophysiological processes associated with HF (58).